Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
企業コードQNTM
会社名Quantum Biopharma Ltd
上場日May 29, 2018
最高経営責任者「CEO」Kotra (Lakshmi P)
従業員数- -
証券種類Ordinary Share
決算期末May 29
本社所在地55 University Ave. , Suite 1003
都市TORONTO
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号M5J 2H7
電話番号14168548884
ウェブサイトhttps://www.quantumbiopharma.com/
企業コードQNTM
上場日May 29, 2018
最高経営責任者「CEO」Kotra (Lakshmi P)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし